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Summary
Objectives:  To  deﬁne  the  epidemiological  and  clinical  features  and  complementary  investi-
gation ﬁndings  of  extranodal  NK/T-cell  lymphoma,  nasal  type  and  to  discuss  the  diagnostic
difﬁculties  and  the  various  treatment  options.
Patients  and  methods:  This  retrospective  study  was  based  on  15  patients  with  extranodal  NK/T-
cell lymphoma,  nasal  type,  managed  between  1990  and  2009.
Results:  This  series  comprised  13  men  and  two  women  (sex  ratio  =  6.5)  with  a  mean  age  of  52
years (range:  35—81  years).  The  mean  time  to  ﬁrst  consultation  was  6  months.  The  most  common
symptoms  were  nasal  obstruction  (87%)  and  purulent  nasal  discharge  (73%),  followed  by  epistaxis
(60%). Physical  examination  demonstrated  the  presence  of  a  tumour  of  the  nasal  cavity  in  11
patients.  The  diagnosis  was  conﬁrmed  by  histological  examination  of  a  biopsy  completed  by
immunohistochemistry.  CT  scan  of  the  facial  bones  was  performed  in  all  patients  of  this  series.
The site  of  extranodal  NK/T-cell  lymphoma  was  essentially  nasal  (12  cases).  Orbital  extension
was observed  in  four  cases,  associated  with  intracranial  extension  in  two  cases  and  osteolysis
was observed  in  11  patients.  Lymphomas  were  classiﬁed  as  stage  IE  in  74%  of  cases  and  stage
IIE in  26%  of  cases.  Only  one  patient  was  lost  to  follow-up  during  treatment.  Three  patients
died before  any  treatment.  Treatment  therefore  concerned  12  patients.  Stage  IE  lymphomas
were treated  by  radiotherapy  and/or  chemotherapy.  All  stage  IIE  lymphomas  were  treated  by
chemotherapy  alone.  Stage  IE  patients  had  a  better  prognosis.
Conclusion:  Extranodal  NK/T-cell  lymphoma,  nasal  type,  is  an  aggressive  form  of  non-Hodgkin’s
lymphoma  comprising  speciﬁc  clinicopathological  characteristics.  The  addition  of  chemothe-
rapy for  advanced  stages  does  not  appear  to  improve  survival  compared  radiotherapy  alone,
which remains  the  treatment  of  choice  especially  for  localized  stages.
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reviously  known  as  lethal  midline  granuloma,  extranodal
K/T-cell  lymphoma,  nasal  type  (ENKL)  is  a  serious  and
served.
1 S.  Tababi  et  al.
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enerally  fatal  disease.  Extranodal  NK/T-cell  lymphoma,
asal  type,  is  a  clinical  entity  causing  necrosis,  preferen-
ially  starting  in  the  nasal  cavities  and  progressively  invading
id-facial  bones,  causing  centrifugal  destruction  of  the
acial  bones  with  no  tendency  to  healing.
Extranodal  NK/T-cell  lymphoma,  nasal  type  is  a  rare
isease  [1],  which  has  now  been  more  clearly  elucidated  as
 result  of  progress  in  immunohistochemistry  and  molecular
iology.
The  pathogenesis  of  this  disease  is  unknown,  but  it  is
elated  to  Epstein-Barr  virus  (EBV)  infection,  which  is  asso-
iated  with  a  poor  prognosis  [1].
A  retrospective  review  of  15  patients  with  extranodal
K/T-cell  lymphoma,  nasal  type,  was  conducted  in  order  to
eﬁne  the  epidemiological  and  clinical  features  and  com-
lementary  investigation  ﬁndings  of  extranodal  NK/T-cell
ymphoma,  nasal  type,  and  to  discuss  the  diagnostic  difﬁ-
ulties  and  the  various  treatment  options.
atients and methods
his  retrospective  study  was  based  on  15  patients  with
xtranodal  NK/T-cell  lymphoma,  nasal  type,  managed  in
he  department  of  Otolaryngology-Head  and  Neck  Surgery
f  Rabta  hospital  in  Tunis  over  a  20-year  period  (January
990—December  2009).
All  patients  in  whom  the  diagnosis  of  extranodal  NK/T-
ell  lymphoma,  nasal  type,  was  conﬁrmed  on  histology  and
mmunohistochemistry  were  included  in  this  study  and  all
istological  slides  labelled  as  midline  granuloma  were  sys-
ematically  reviewed.
All  information  available  in  medical  ﬁles,  including  epi-
emiological  and  clinical  data  results  of  complementary
nvestigations  and  treatment  modalities,  was  collected  and
nalysed.
The  mean  follow-up  of  this  series  was  13.6  months
range:  2—62  months).
esults
his  series  comprised  15  patients,  most  of  whom  (11
atients,  i.e.  73%  of  the  series)  were  diagnosed  between
999  and  2006,  i.e.  a  mean  of  one  case  per  year.  A  marked
ale  predominance  was  observed,  with  a  sex  ratio  of  6.5
13  M/2  F).  The  mean  age  of  patients  in  this  series  was  52
ears  (range:  35—81  years)  and  the  mean  time  to  ﬁrst  consul-
ation  was  6  months.
The  presenting  complaint  in  the  majority  of  cases  (13
atients)  was  nasal  obstruction  associated  with  purulent
asal  discharge  (11  patients)  and  epistaxis  (nine  patients).
wo  patients  presented  decreased  visual  acuity,  while  one
atient  presented  with  blindness.  Upper  dysphagia  with
 history  of  aspiration  was  reported  by  two  patients  due
o  tumour  extension  into  the  oropharynx.  Five  patients
resented  marked  alteration  of  performance  status  with
uctuating  fever  in  two  cases.
Inspection  of  the  face  revealed  the  presence  of  a  malar
welling  in  two  patients  and  a  mandibular  swelling  in
nly  one  patient.  Hemifacial  oedema  was  observed  in  two
atients  and  deformity  of  the  nasal  pyramid  was  observed
c
n
iigure  1  a:  left  exophthalmos  with  chemosis;  b:  necrotic
lceration  of  the  mucosa  of  the  hard  palate.
n  four  patients.  Exophthalmos  was  noted  in  three  patients,
ssociated  with  chemosis  in  two  patients  (Fig.  1a).
Nasal  endoscopy,  performed  in  all  patients,  demon-
trated  an  ulcerative  and  necrotic,  friable  and  haemorrhagic
umour  ﬁlling  the  nasal  cavities  in  11  patients,  while  no
bnormality  was  detected  in  the  other  patients.  The  tumour
as  responsible  for  deviation  of  the  nasal  septum  in  three
ases.
Examination  of  the  oral  cavity  and  oropharynx  demon-
trated  necrotic  ulceration  of  the  mucosa  of  the  hard  palate
n  three  cases,  resulting  in  an  oronasal  communication  in
ne  case  (Fig.  1b).
Cervical  lymphadenopathy  was  demonstrated  in  three
atients.  A  cranial  nerve  lesion  was  observed  in  four
atients,  comprising  concomitant  lesions  of  the  2nd,  3rd,
th  and  5th  cranial  nerves  in  one  patient.
Biopsies  were  performed  in  all  patients  and  histologi-
al  examination  completed  by  immunohistochemical  study
onﬁrmed  the  diagnosis  of  extranodal  NK/T-cell  lymphoma,
asal  type,  in  every  case.
Histological  examination  demonstrated  lymphomatous
nvasion  of  the  lamina  propria  composed  of  sheets
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Figure  3  Immunohistochemical  study.
A. Tumour  cells  are  positive  for  anti-CD56  antibody  (CD56  ×  25).
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remission  with  a  mean  follow-up  of  46  months.Figure  2  A.  Great  lymphomatous  cells  with  clear  cytoplasm
(HE ×  10).  B.  Tumour  cells  destroying  the  vessel  walls  (HE  ×  25).
of  medium-sized  to  large  cells  with  clear  cytoplasm
(Fig.  2a).  Tumour  cells  were  sometimes  arranged  in
‘‘angiocentric’’  perivascular  cuffs  destroying  the  vessel
wall  (‘‘angiodestructive’’)  with  haemorrhagic  suffusions  and
tumour  necrosis  (Fig.  2b).
Immunohistochemical  examination  demonstrated,  in
every  case,  intense  and  diffuse  positive  cytoplasmic  stain-
ing  of  tumour  cells  by  anti-CD3  antibody  and  negative  stai-
ning  for  anti-CD20  antibody  and  cytokeratin.  CD56  staining
was  positive  for  all  patients,  while  CD30  (performed  in  nine
cases)  was  positive  in  only  six  patients  (Fig.  3).
Computed  tomography  (CT)  of  the  facial  bones  was  per-
formed  in  all  patients,  completed  by  magnetic  resonance
imaging  (MRI)  in  four  patients.  The  NK/T-cell  lymphoma  was
essentially  located  in  the  nasal  cavity  (12  patients).  Sinus
involvement  concerned  the  ethmoid  sinus  in  seven  patients,
the  maxillary  sinus  in  six  patients,  the  frontal  sinus  in  three
patients  and  the  sphenoid  sinus  in  only  one  patient.
Orbital  extension  was  observed  in  four  patients,  associ-
ated  with  intracranial  extension  in  two  patients  (Fig.  4).
Extension  to  the  nasopharynx  was  present  in  three  patients,
associated  with  extension  to  the  oropharynx  in  two  patients.
Osteolysis  was  demonstrated  in  11  patients.  Soft  tissue  inva-
sion  was  demonstrated  in  ﬁve  patients,  involving  the  malar
s
c. Epitheliotropism:  tumour  cells  penetrating  into  cytokeratin-
abelled  glands  (cytokeratin  ×  40).
ucosa  in  two  patients,  premandibular  soft  tissues  in  one
atient  (Fig.  5)  and  frontal  subcutaneous  soft  tissues  in  one
atient.
Patients  were  staged  according  to  the  Ann  Arbor  classi-
cation  (Table  1)  as  stage  IE  in  11  cases  (73%)  and  stage  IIE
n  four  cases  (26%).  Three  patients  died  before  initiation  of
reatment  in  a  context  of  septic  shock.
Radiotherapy  alone  was  performed  for  four  patients
ith  stage  IE  disease.  Combined  treatment  (radiothe-
apy  and  chemotherapy)  was  administered  to  four  patients
ith  diffuse  stage  IE,  while  cyclophosphamide,  doxorubicin,
incristine,  prednisolone  (CHOP)  chemotherapy  alone  was
dministered  in  four  patients:  three  stage  IIE  patients  and
ne  patient  with  diffuse  stage  IE  disease.
Most  patients  had  a  poor  outcome  and  nine  patients  died:
wo  during  radiotherapy,  one  during  chemoradiotherapy  and
hree  during  chemotherapy.  Only  four  patients  are  in  clinicalFollow-up  head  and  neck  CT  scan  was  performed  in
even  patients,  demonstrating  complete  radiological  eradi-
ation  of  the  lesions  in  four  cases.  Progressive  disease  was
144  S.  Tababi  et  al.
Figure  4  Axial  (A)  and  coronal  (B)  CT  scans  of  facial  bones:
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Figure  5  Unenhanced  CT  of  the  facial  bones  (axial  scan):
a mass  over  the  anterior  surface  of  the  left  horizontal  ramus
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delayed  management,  as  the  clinical  presentation  of  thissteolysis  of  the  medial  wall  of  the  orbit  and  the  superior  wall
f the  left  frontal  sinus  with  orbital  and  intracranial  extension.
bserved  in  only  one  patient  in  this  series.  This  patient
ad  received  radiotherapy  for  a  very  large  space-occupying
aso-ethmoido-frontal  lesion  with  orbital  and  intracranial
xtension,  followed  by  intensive  chemotherapy.  This  patient
urrently  presents  stable  disease  after  the  4th  cycle  of
hemotherapy.
The  mean  follow-up  of  this  series  was  13.6  months
range:  2—62  months).
iscussion
xtranodal  NK/T-cell  lymphoma,  nasal  type,  is  a  clinical
ntity  comprising  ulcerative  and  necrotic  lesions  preferen-
ially  arising  in  the  nasal  cavities  and  sinuses  (70%),  but
hich  can  also  arise  at  the  expense  of  Waldeyer’s  ring  (38%),
he  oral  cavity  (14%),  larynx,  hypopharynx  (10%)  and  even  in
he  mandible  or  cheek  [2].
d
t
wf the  mandible  measuring  58  × 41  ×  35  mm  with  inﬁltration  of
djacent  fat.
The  incidence  of  extranodal  NK/T-cell  lymphoma,  nasal
ype,  varies  considerably  in  different  parts  of  the  world,
ut  it  remains  a  rare  disease  since  the  ﬁrst  description  in
933.  However,  the  number  of  new  cases  per  year  is  on  the
ncrease  due  to  a  better  knowledge  of  this  disease.  Extran-
dal  NK/T-cell  lymphoma,  nasal  type,  represents  45%  of  all
rimary  nasal  lymphomas,  while  T-cell  lymphoma  represents
nly  21%  of  all  primary  nasal  lymphomas  [3].
Extranodal  NK/T-cell  lymphoma,  nasal  type,  can  occur  at
ny  age,  but  essentially  affects  subjects  during  the  fourth
nd  ﬁfth  decades  [1].  The  mean  age  of  the  patients  in  our
eries  was  52  years  (range:  35—81  years).
Extranodal  NK/T-cell  lymphoma,  nasal  type,  is  more  fre-
uent  in  men  and  the  sex  ratio  varies  between  2  and  4.5  in
he  literature  [4,5]  with  a  sex  ratio  of  6.5  in  our  series.
The  pathogenesis  of  extranodal  NK/T-cell  lymphoma,
asal  type,  is  unknown.  However,  it  is  strongly  associated
ith  Epstein-Barr  virus  (EBV)  infection  [1].  EBV  infection  is
ssociated  with  a  poor  prognosis  with  a  high  local  recurrence
ate,  possible  extension  to  other  extranodal  areas  and  deve-
opment  of  macrophage  activation  syndrome  [5],  the  most
readed  complication  that  occurs  in  8  to  12%  of  cases  due  to
ecretion  of  cytokines  by  tumour  cells,  frequently  inducing
ystemic  symptoms  such  as  fever  and  weight  loss  [5].
Some  studies  have  attributed  these  lymphomas  to  over-
xpression  of  protein  p53,  possibly  associated  with  a  p53
ene  mutation,  often  induced  by  the  presence  of  EBV  [6].
Extranodal  NK/T-cell  lymphoma,  nasal  type,  is  a  rare  dis-
ase  characterized  by  polymorphic  clinical  features  that  can
ccount  for  the  diagnostic  difﬁculties  and  the  frequentlyisease  is  non-speciﬁc  and  can  often  be  misleading,  resul-
ing  in  an  incorrect  diagnosis.  This  misleading  appearance
as  observed  by  Kyrmizakis  et  al.  [7]  in  their  series  of  three
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Table  1  Ann  Arbor  staging.
Stage  Deﬁnition
I  Involvement  of  a  single  lymph  node  region
II Involvement  of  two  or  more  lymph  node  regions  on  the  same  side  of  the  diaphragm
(the mediastinum  is  a  single  site,  hilar  lymph  nodes  are  each  counted  as  a  site)
III Involvement  of  several  lymph  node  regions  on  both  sides  of  the  diaphragm
E designation,  when  applicable,
to  stages  I,  II  or  III
Extranodal  disease  contiguous  to  lymph  node  involvement  that  can  be  encompassed
within an  irradiation  ﬁeld;  different  from  the  disseminated  nature  of  stage  IV  disease
IV Diffuse  or  disseminated  foci  of  involvement  of  one  or  more  extralymphatic  organs  or
tissues, with  or  without  associated  lymphatic  involvement
Symptoms
A No  symptoms
B At  least  one  of  the  following  symptoms
Unexplained  weight  loss  of  >  10%  of  body  weight  during  the  6  months  before
staging investigation
Unexplained  fever  with  temperatures  >  38 ◦C  for  at  least  7  days
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cases,  in  which  extranodal  NK/T-cell  lymphoma,  nasal  type,
was  initially  mistaken  for  chronic  sinusitis.
Most  patients  present  a  localized  lesion  with  nasal
obstruction  caused  by  an  aggressive  tumour  invading  the
sinuses,  palate  and  nasal  cavities  [8].  Symptoms  consist
of  non-speciﬁc  nasal  symptoms  (epistaxis,  nasal  obstruc-
tion,  nasal  discharge),  dysphagia,  hemifacial  pain  or  facial
oedema  [4].  Twenty  to  40%  of  cases  present  a  dissemi-
nated  form  consisting  of  generalized  granulomatosis  with
cutaneous,  subcutaneous,  ocular,  gastrointestinal,  lung  and
nerve  involvement  [5,9,10].
It  is  now  generally  accepted  that  a  large  number
of  biopsies  must  be  performed  to  conﬁrm  the  diagno-
sis  of  extranodal  NK/T-cell  lymphoma,  nasal  type  [11].
The  histological  features  of  NK/T-cell  lymphoma  are  simi-
lar  regardless  of  the  site  of  the  lesion  [5,10], consisting
of  sheets  of  atypical  small,  medium-sized,  large  or  giant
Sternberg-like  cells.
The  characteristic  feature  of  extranodal  NK/T-cell  lym-
phoma,  nasal  type,  is  the  presence  of  vascular  lesions  with
tumour  cells  arranged  in  perivascular  (angiocentric)  cuffs,
with  occasional  penetration  of  these  cells  across  the  vessel
wall  and  proliferation  in  the  lumen,  causing  vascular  thrombi
(angiodestructive  lesions).  Areas  of  necrosis  and  ﬁbrosis  are
observed,  with  marginal  pseudoepitheliomatous  hyperplasia
of  the  nasal  mucosa  [12].
Immunophenotyping  reveals  expression  of  T  lympho-
cyte  as  well  as  NK  lymphocyte  cell  markers,  hence  the
term:  extranodal  NK/T-cell  lymphoma  [13]. The  most  typical
immunophenotype  of  extranodal  NK/T-cell  lymphoma,  nasal
type,  is:  CD2+,  CD56+,  which  is  the  speciﬁc  marker  of  NK,
cells  with  intracytoplasmic  expression  of  anti-CD3  antibody
and  negative  expression  of  CD3  on  the  cell  surface  [14].
EBV  can  be  detected  in  tumour  cells  in  the  great  majo-
rity  of  cases,  as  conﬁrmed  by  several  immunolabelling  and
molecular  biology  studies  [15].
Cytogenetic  studies  have  concluded  on  the  presence  of
a  variety  of  cytogenetic  aberrations,  such  as  mutation  of
p
d
l
ts
he  Fas  and  p53  tumour  suppressor  genes  [16]. However,  the
ost  common  cytogenetic  abnormality  is  a  deletion  in  the
21  q25  region  or  the  p10  region  of  chromosome  6.
Computed  tomography  is  the  essential  examination  for
nvestigation  of  extranodal  NK/T-cell  lymphoma,  nasal  type.
t  allows  precise  staging  of  the  lesions  by  deﬁning  the  tumour
ite,  the  presence  of  osteolysis  and  possible  extension  to
djacent  structures  [17]. It  is  also  essential  for  pretreatment
valuation,  assessment  of  the  response  to  treatment  and
ollow-up.
MRI  more  reliably  demonstrates  soft  tissue  invasion,
s  it  is  able  to  distinguish  inﬂammation  and  soft  tissue
edema  from  tumour  invasion.  MRI  shows  a  lesion  with  a
omogeneous  low  to  intermediate  intensity  signal,  which  is
sointense  to  muscles  on  T1-weighted  sequences  and  mod-
rately  hyperintense  to  muscle  on  T2-weighted  sequences
nd  hypointense  to  mucus.  Gadolinium  enhancement  is  also
oderate  and  heterogeneous  and  is  useful  to  evaluate  the
natomical  relations  of  the  tumour  with  intracranial  struc-
ures  [1].
The  laboratory  work-up  is  non-speciﬁc  and  of  little  value
or  the  positive  diagnosis  of  this  disease  [18].
When  the  diagnosis  of  extranodal  NK/T-cell  lymphoma,
asal  type,  has  been  conﬁrmed,  a  staging  assessment
ust  be  performed  prior  to  any  treatment,  comprising
hysical  examination  looking  for  superﬁcial  lymph  nodes,
epatomegaly  or  splenomegaly,  chest  x-ray,  abdominal
ltrasound,  chest  and  abdomen  CT,  bone  marrow  biopsy,  gas-
rointestinal  endoscopy  and  possibly  lumbar  puncture  in  the
resence  of  a  lesion  of  the  skull  base  [18].
Despite  progress  in  immunohistochemistry  and  molecu-
ar  biology,  extranodal  NK/T-cell  lymphoma,  nasal  type,  still
emains  a  diagnosis  of  exclusion  due  to  the  absence  of  any
peciﬁc  clinical  and  histological  features.  Many  diseases  can
resent  in  the  form  of  nasal  and  mid-facial  ulceration  and
estruction,  similar  to  that  caused  by  extranodal  NK/T-cell
ymphoma  [19], such  as  Wegener’s  granulomatosis,  syphilis,
uberculosis,  other  malignant  tumours  and  cocaine  abuse.
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The  treatment  of  extranodal  NK/T-cell  lymphoma,  nasal
ype,  is  difﬁcult  and  complex.  Some  authors  consider  that
urgery  is  ineffective  and  may  even  cause  deterioration  of
he  lesions  by  inducing  rapid  progression  of  the  disease.  Sur-
ical  resection  of  the  lesions  has  been  proposed,  essentially
or  diagnostic  purposes,  but  also  to  promote  drainage  of
ecrotic  cavities.
External  beam  radiotherapy  with  a  minimum  dose  of
bout  52  Gy  delivered  according  to  classical  fractionation
s  recommended  for  localized  stages  (stages  I and  II)  [5].  It
chieves  complete  remission  in  40  to  80%  of  cases  with  a
-year  overall  survival  of  between  40  and  59%  [20].
Aggressive  chemotherapy  is  the  only  available  treatment
ption  for  advanced  forms  (stage  III  and  IV),  inducing  a  com-
lete  response  in  less  than  15%  of  cases  [21]. According
o  the  study  by  Hatta  et  al.  [22], CHOP  chemotherapy  in
ombination  with  radiotherapy  is  ineffective  for  advanced
xtranodal  NK/T-cell  lymphoma,  nasal  type,  beyond  stage
IE  and  stage  B  NK/T-cell  lymphoma.  This  combination  could
lso  signiﬁcantly  improve  survival  in  stage  IE  and  IIE  NK/T-
ell  lymphoma  [21].
Other  so-called  ‘‘salvage’’  chemotherapy  protocols  are
ometimes  used  in  the  absence  of  response  to  ﬁrst-line
hemotherapy  or  in  the  case  of  early  relapse,  consisting
f  intensive  chemotherapy  (2nd  or  3rd  generation  combi-
ation  chemotherapy)  (ranimustine,  etoposide,  carboplatin
nd  cyclophosphamide),  possibly  followed  by  autologous
one  marrow  transplantation  [5].  According  to  Mikhaeels
nd  Spittle  [23], intensive  chemotherapy  is  necessary  even
or  localized  stages  due  to  the  highly  aggressive  nature  of
his  lymphoma.  Chemotherapy  is  now  increasingly  replaced
y  haematopoietic  stem  cell  transplantation  or  addition  of
rowth  factors.  Interferon  therapy  has  not  been  shown  to  be
ffective.
This  tumour  has  a  poor  prognosis,  with  a  5-year  overall
urvival  ranging  between  10  and  45%  depending  on  the  series
24,25].
onclusion
xtranodal  NK/T-cell  lymphoma,  nasal  type,  is  a  rare
isease,  but  the  number  of  new  cases  reported  each  year
as  been  continually  increasing  over  recent  years  due  to
 better  knowledge  of  this  disease.  This  disease  has  been
ore  clearly  elucidated  as  a  result  of  progress  in  immuno-
istochemistry  and  molecular  biology.
Extranodal  NK/T-cell  lymphoma,  nasal  type,  is  charac-
erized  by  its  polymorphic  clinical  features,  responsible  for
iagnostic  difﬁculties  and  frequently  delayed  management.
istological  examination  of  biopsy  samples  completed  by
mmunohistochemistry  is  essential  to  establish  the  positive
iagnosis.
The  pathogenesis  of  extranodal  NK/T-cell  lymphoma,
asal  type,  is  unknown,  but  it  is  strongly  associated  with
pstein-Barr  virus  infection.  These  EBV-associated  lym-
homas  have  a  poor  prognosis  with  a  high  local  recurrence
ate  and  the  presence  of  macrophage  activation  syndrome
n  the  majority  of  cases.
Optimal  management  of  extranodal  NK/T-cell  lymphoma,
asal  type,  must  be  based  on  multidisciplinary  collaboration
etween  otorhinolaryngologists,  radiotherapists,  medical
[S.  Tababi  et  al.
ncologists  and  nutritionists  in  order  to  improve  the  prog-
osis  of  this  disease.
EBV  immunotherapy,  monoclonal  antibodies  and  gene
herapy  have  been  proposed  as  possible  treatments  for  the
uture,  as  the  EBV  virus  could  become  a  major  therapeu-
ic  target  in  combination  with  conventional  combination
hemotherapy.  Research  into  p53  expression  is  currently
nderway  to  elucidate  the  carcinogenesis  of  extranodal
K/T-cell  lymphoma  and  probably  also  as  an  approach  to  the
reatment  and  prognosis  of  these  aggressive  lymphomas.
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